公开(公告)号：US20250064964A1

公开(公告)日：2025-02-27

申请号：US18937914

申请日：2024-11-05

Applicant: Novartis AG

Inventor： Anthony Edward Boitano ,  Matthew Burger ,  Susan E. Cellitti ,  Michael P. Cooke ,  Catrin Finner ,  Bernhard Hubert Geierstanger ,  Yunho Jin ,  Si Tuen Lee-Hoeflich ,  HongNgoc Thi Pham ,  Siew Ho Schleyer ,  Kathrin Tissot ,  Tetsuo Uno ,  Ben Wen

IPC: A61K47/68 ,  A61K38/07 ,  A61K38/12 ,  C07K16/28

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoetic stem cells in a patient in need thereof.

公开(公告)号：US11357864B2

公开(公告)日：2022-06-14

申请号：US16470897

申请日：2017-12-19

Applicant: NOVARTIS AG

Inventor： Ben Wen ,  Anthony E. Boitano ,  Matthew Burger ,  Susan E. Cellitti ,  Michael P. Cooke ,  Catrin Finner ,  Bernhard Hubert Geierstanger ,  Yunho Jin ,  Si Tuen Lee-Hoeflich ,  HongNgoc Thi Pham ,  Siew Ho Schleyer ,  Kathrin Tissot ,  Tetsuo Uno

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C07K16/46 ,  A61K47/68 ,  A61K38/07 ,  A61K38/12 ,  C07K16/28

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

公开(公告)号：US12171839B2

公开(公告)日：2024-12-24

申请号：US17833077

申请日：2022-06-06

Applicant: Novartis AG

Inventor： Anthony Edward Boitano ,  Matthew Burger ,  Susan E. Cellitti ,  Michael P. Cooke ,  Catrin Finner ,  Bernhard Hubert Geierstanger ,  Yunho Jin ,  Si Tuen Lee-Hoeflich ,  HongNgoc Thi Pham ,  Siew Ho Schleyer ,  Kathrin Tissot ,  Tetsuo Uno ,  Ben Wen

IPC: C07K16/00 ,  A61K38/07 ,  A61K38/12 ,  A61K47/68 ,  C07K16/28 ,  C07K16/46

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

公开(公告)号：US20200165322A1

公开(公告)日：2020-05-28

申请号：US16716137

申请日：2019-12-16

Applicant: Novartis AG

Inventor： Kathrin Tissot ,  Stefan Ewert ,  Adrian Auf Der Maur ,  Alcide Barberis ,  Dominik Escher

IPC: C07K16/00 ,  G01N33/68

Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.